Last reviewed 2026-04-22 · How we verify

FMS azithromycin tablets

Azithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.

Azithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Used for Bacterial infections including respiratory tract infections, skin and soft tissue infections, and sexually transmitted infections, Otitis media and sinusitis.

At a glance

Mechanism of action

Azithromycin binds to the bacterial 50S ribosomal subunit and inhibits peptide translocation, preventing the formation of the initiation complex and blocking bacterial protein synthesis. This bacteriostatic action is effective against a broad spectrum of gram-positive and gram-negative bacteria, as well as some atypical organisms. The drug accumulates in tissues and has a long half-life, allowing for extended dosing intervals.

Approved indications

• Bacterial infections including respiratory tract infections, skin and soft tissue infections, and sexually transmitted infections
• Otitis media and sinusitis

Common side effects

• Diarrhea
• Nausea
• Abdominal pain
• Vomiting
• QT prolongation
• Hepatotoxicity

Key clinical trials

• Treatment of Periodontitis by Conventional 4 Weekly Sections or Within 24 Hours (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• FMS azithromycin tablets CI brief — competitive landscape report
• FMS azithromycin tablets updates RSS · CI watch RSS
• University of Taubate portfolio CI